The stock has recorded a consecutive gain over the last five trading days, delivering a cumulative return of 4.26% during this period. This upward trajectory has positioned Laurus Labs comfortably above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling robust technical strength. The day’s performance also saw the stock outperform its sector by 1.01%, underscoring its relative strength within the Pharmaceuticals & Biotechnology space.
Over the past year, Laurus Labs has demonstrated remarkable growth, with its stock price appreciating by 112.18%, significantly outpacing the Sensex’s 9.46% return over the same timeframe. The stock’s 52-week low was recorded at Rs.475.45, highlighting the substantial price appreciation witnessed in the last twelve months.
Fresh entry alert! This mid-cap from Pharmaceuticals & Biotechnology sector is already turning heads in our Top 1% club. Get ahead of the market now!
- New Top 1% entry
- Market attention building
- Early positioning opportunity
From a financial perspective, Laurus Labs has exhibited strong operational metrics. The company’s return on capital employed (ROCE) stands at 16.75%, indicating efficient utilisation of capital resources. The net profit growth reported in the September quarter was substantial, with a rise of 993.4%, reflecting very positive quarterly results. This marks the fourth consecutive quarter of positive results for the company.
Profit before tax (PBT) excluding other income for the quarter was Rs.242.77 crore, showing a growth of 1233.17%, while profit after tax (PAT) for the same period was Rs.194.97 crore, representing an increase of 882.7%. The operating profit to interest ratio reached a high of 10.08 times, highlighting strong earnings relative to interest expenses.
Institutional investors hold a significant stake in Laurus Labs, with 37.63% ownership. This level of institutional holding often reflects a thorough analysis of the company’s fundamentals by investors with substantial resources and expertise.
Get the full story on Laurus Labs ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- Full research story
- Sector comparison done
- Informed decision support
Despite the strong recent performance, the company’s operating profit has grown at an annual rate of 5.37% over the last five years, indicating a more moderate long-term growth trend. The valuation metrics show a ROCE of 14.9 and an enterprise value to capital employed ratio of 8.2, suggesting a relatively high valuation compared to historical averages. However, the stock is currently trading at a discount relative to its peers’ average historical valuations.
Over the past year, while the stock price has appreciated by 112.18%, the company’s profits have risen by 421.7%, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.2. This metric provides insight into the relationship between the company’s earnings growth and its market valuation.
On the broader market front, the Sensex opened 91.42 points higher but later declined by 393.30 points, trading at 84,649.07, down 0.36%. The benchmark index remains 0.76% away from its own 52-week high of 85,290.06. The Sensex is currently trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a bullish trend in the broader market context.
Laurus Labs’ recent milestone of reaching Rs.1033.55 as its new 52-week high is a noteworthy achievement within this market environment. The stock’s ability to sustain gains above multiple moving averages and outperform its sector highlights the momentum behind this rally. The combination of strong quarterly financial results, efficient capital utilisation, and significant institutional backing has contributed to this upward movement.
Investors and market participants observing Laurus Labs will note the stock’s consistent performance over the past year and its capacity to maintain positive quarterly results. The stock’s trajectory reflects a blend of operational strength and market confidence, as evidenced by its technical indicators and financial metrics.
As Laurus Labs continues to trade near its peak levels, the stock remains a significant presence in the Pharmaceuticals & Biotechnology sector, demonstrating resilience and growth in a competitive industry landscape.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
